Compare Heron Therapeutics Inc (HRTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Consumer Staples Select Sector SPDR Fund trades at $84.8. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLP | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $90.00 |
52-Week Low | $0.39 | $75.61 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
XLP trades at $84.86, down 0.39% on the day, with a bullish technical signal supported by moving averages. The ETF maintains a 2.6% dividend yield and shows strength in defensive positioning amid market volatility. Analyst consensus is unanimously positive with 2 buy ratings and no hold or sell recommendations.
The consumer staples ETF offers defensive exposure during economic uncertainty, with technical indicators supporting near-term upside potential. Key risks include sector concentration and competition from broader alternatives. Current levels near pivot point resistance at $86 represent the immediate technical challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
